New combo therapy targets Hard-to-Treat cancers
NCT ID NCT07241936
First seen Nov 21, 2025 · Last updated May 01, 2026 · Updated 14 times
Summary
This study tests a combination of a special form of sirolimus (a drug that slows cancer growth) with different antibody-drug conjugates (ADCs, which deliver powerful medicine directly to cancer cells) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the safest dose and check for side effects. About 444 adults aged 18 to 75 with good organ function and at least one measurable tumor are eligible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.